181 related articles for article (PubMed ID: 38144527)
1. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
[TBL] [Abstract][Full Text] [Related]
2. Isatuximab: A Review of Its Use in Multiple Myeloma.
Frampton JE
Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
[TBL] [Abstract][Full Text] [Related]
3. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
Ye W; Wu X; Liu X; Zheng X; Deng J; Gong Y
BMC Cancer; 2021 Sep; 21(1):994. PubMed ID: 34488679
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials.
Moraes FCA; Sano VKT; Lôbo AOM; Kelly FA; Morbach V; Pasqualotto E; Burbano RMR
J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672988
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
7. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
[TBL] [Abstract][Full Text] [Related]
8. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Mateos MV; Weisel K; De Stefano V; Goldschmidt H; Delforge M; Mohty M; Cavo M; Vij R; Lindsey-Hill J; Dytfeld D; Angelucci E; Perrot A; Benjamin R; van de Donk NWCJ; Ocio EM; Scheid C; Gay F; Roeloffzen W; Rodriguez-Otero P; Broijl A; Potamianou A; Sakabedoyan C; Semerjian M; Keim S; Strulev V; Schecter JM; Vogel M; Wapenaar R; Nesheiwat T; San-Miguel J; Sonneveld P; Einsele H; Moreau P
Leukemia; 2022 May; 36(5):1371-1376. PubMed ID: 35332278
[TBL] [Abstract][Full Text] [Related]
9. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Wei Y; He L; Liu T; Guo T; Xie C; Jia J; Lin Y; Liu J; Fan J
Front Pharmacol; 2024; 15():1372077. PubMed ID: 38584601
[No Abstract] [Full Text] [Related]
12. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
[TBL] [Abstract][Full Text] [Related]
13. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
[TBL] [Abstract][Full Text] [Related]
14. Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
Gu X; Sun C; Xu J; Lin Z; Zhang L; Zheng Y
Hematology; 2023 Dec; 28(1):2187972. PubMed ID: 36920065
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Xu H; Guan C; Xu P; Zhou D; Xu Y; Chen B; Bai H
Front Oncol; 2024; 14():1355643. PubMed ID: 38651157
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
[TBL] [Abstract][Full Text] [Related]
17. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
Shah B; Gray J; Abraham I; Chang M
J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
[TBL] [Abstract][Full Text] [Related]
18. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.
Harvanová Ľ; Štulajterová V; Guman T; Ladická M; Hlebašková M; Chudej J; Šimek M; Štecová N; Flochová E; Kubala J; Simančíková I; Drgoňa Ľ; Vranovský A; Wild A; Mistrík M; Bátorová A
Neoplasma; 2021 May; 68(3):626-630. PubMed ID: 33567854
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
